What Evolus, Inc. does.

We are a global performance beauty company delivering breakthrough products with a customer-centric approach. Our primary market is the cash-pay aesthetic market, which consists of medical products that consumers pay for directly out of pocket. Our customers are aesthetic practitioners who are properly licensed to deliver our products. By avoiding the regulatory burdens that accompany reimbursed products and pursuing an aesthetic-only non-reimbursed product strategy, we believe that we create flexibility to deliver a unique value proposition to our customers. We utilize this flexibility to drive customer adoption efforts through programs such as our consumer loyalty program, co-branded marketing programs, promotional events and pricing strategies.

Our current commercially available products and our product candidates represent two of the largest product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid (“HA”) gels.

Jeuveau ® is a proprietary 900 kilodalton (“kDa”), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as “frown lines,” in adults. Jeuveau ® offers a 900 kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). We believe aesthetic practitioners generally prefer the performance characteristics of the complete 900 kDa neurotoxin complex and are accustomed to injecting this formulation.

Revenue and profit, by fiscal year.

More on EOLS.

• Evolus, Inc. summary
• Evolus, Inc. financial statements
• Evolus, Inc. key metrics
• Evolus, Inc. health scores and style box
• Evolus, Inc. earnings
• Evolus, Inc. dividends
• Evolus, Inc. valuation
• Evolus, Inc. ownership and insiders
• Evolus, Inc. peers

Figures from Evolus, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.